spacer
home > pmps > winter 2019 > goals for greater tablet production
PUBLICATIONS
Pharmaceutical Manufacturing and Packing Sourcer

Goals for Greater Tablet Production

The global pharmaceutical and medicine manufacturing industry were reported to have reached revenue of US $1 trillion in 2018, with the most popular form of pharmaceutical drug being solid dosage. It is convenient, quick to produce, and cost-effective to manufacture (1).

The goal for tablet manufacturers is to mass produce quality products in a cost-effective way, but achieving this requires careful consideration.

Is Design Working?

One of the first ‘goals’ for greater productivity is the tablet design; if this is incorrect, production will be severely affected. To produce robust tablets, the importance of detailed design should not be overlooked, as it is key to the quality of the end product.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Alex Bunting manages the marketing team at I Holland, is an English graduate, and a member of the Institute of Digital Marketing. He joined I Holland in April 2008, having spent previous years working in environmental science. Alex was instrumental in the design of the 2010 edition of the widely adopted Eurostandard educational animations and hosts I Holland’s extensive webinar programme.
spacer
Alex Bunting
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Destiny Pharma appoints MedPharm to develop new XF-platform drug formulations

Destiny Pharma, a clinical stage biotechnology company focused on the development of novel antimicrobial drugs, is pleased to announce that it has appointed MedPharm as its expert partner to develop new topical formulations of the Company’s novel XF-platform compounds. These new treatments for dermal and ocular infections are part of its second clinical programme to address the global problem of anti-microbial resistance (AMR). MedPharm is a world leading contract provider of topical and transdermal product design and formulation development services using sophisticated in vitro models to de-risk development programmes.
More info >>

White Papers

Case Study: Cmed’s Mobile Data Management Solution

Cmed Clinical Services

The trial presented to Cmed was a randomized, double blinded, placebo and active controlled study to evaluate the cardiac safety of multiple doses of [study drug] in health volunteers. The pharmaceutical company, who were into the second year of development of a potential blockbuster compound for the treatment of chronic myelogenous leukaemia (CML), were requested by the FDA to design a trial to provide information on the cardiac safety of different dose levels of the study drug in healthy adult volunteers. The primary objective of the study was specifically to find the maximum tolerated dose before QTc levels became unsafe. All development of the compound was put on hold until the results of this study were submitted to the FDA and approval granted for the compound to progress into full development.
More info >>

 
Industry Events

SAPHEX 2019

23-24 October 2019, GALLAGHER CONVENTION CENTRE, 10 RICHARDS DRIVE, HALFWAY HOUSE, MIDRAND, 1685, SOUTH AFRICA

SAPHEX 2019 will be held on the 23rd-24th October at the Gallagher Convention Centre, Johannesburg, South Africa.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement